文献速递骨肌神经CT

双能CT评估脊柱痛风石治疗反应:一例病例报告

Assessing tophaceous spinal gout treatment response using dual-energy CT as a point-of-care imaging modality: case report.
PubMed 文献 · Skeletal Radiol · 2022-12-23

本文报告一例67岁慢性痛风石性痛风患者,血清尿酸549 µmol/L,未接受降尿酸治疗,因腰背痛加重就诊。基线双能CT显示手、肘、足、膝及腰椎(包括左侧L5-S1小关节突入神经孔)存在单钠尿酸盐沉积。经非布司他80 mg和秋水仙碱0.3 mg每日一次治疗2.5年后,血清尿酸降至目标范围(<360 µmol/L),随访双能CT显示脊柱及所有受累外周关节的尿酸盐沉积几乎完全消退。这是首例影像学证据显示降尿酸治疗后脊柱痛风尿酸盐沉积几乎完全消退的报道。

要点

  • 双能CT可无创显示脊柱痛风尿酸盐沉积并评估治疗反应。
  • 慢性痛风患者腰背痛需考虑脊柱痛风,双能CT有助于明确病因。
  • 降尿酸治疗达标后脊柱痛风石可几乎完全消退。

关键影像表现/征象

  • 基线双能CT显示单钠尿酸盐沉积于手、肘、足、膝及腰椎,包括左侧L5-S1小关节并突入神经孔。
  • 随访双能CT显示脊柱(包括受累小关节和神经孔)及所有受累外周关节的尿酸盐沉积几乎完全消退。

诊断标准与关键数值

  • 基线血清尿酸549 µmol/L;治疗2.5年后血清尿酸<360 µmol/L(目标范围)。
  • 双能CT用于显示单钠尿酸盐沉积及其变化。

临床应用与阅片要点

  • 对慢性痛风石性痛风患者出现腰背痛时,应想到脊柱痛风可能,双能CT可帮助识别尿酸盐沉积。
  • 双能CT可用于无创监测降尿酸治疗后的尿酸盐负荷变化。

局限性

  • 单例病例报告,证据级别有限,结论需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

We describe a case of chronic tophaceous gout affecting the spine, hands, elbows, feet, and knees in a 67-year-old man with serum urate levels at 549 µmol/L whose response to treatment was successfully mapped using dual-energy computed tomography (DECT). The patient presented with exacerbation of acute-on-chronic lumbar back pain. He had received a diagnosis of gout 3 years prior to this presentation yet was not on any urate-lowering therapy. The patient received febuxostat 80 mg and colchicine 0.3 mg once daily and underwent DECT to assess baseline monosodium urate (MSU) burden. At baseline, MSU deposits were seen in the hands, elbows, feet, knees, and lumbar spine including the left L5-S1 facet joint encroaching onto the neural foramen. After 2.5 years of treatment, serum urate level was within the target range (< 360 µmol/L), and the patient underwent a follow-up DECT that revealed almost full resolution of MSU deposition in the spine, including the MSU-burdened facet joint and neural foramen in the lumbar spine, in addition to all the affected peripheral joints. This case is the first report of radiological evidence of nearly complete resolution of MSU deposits in spinal gout on DECT after urate-lowering therapy treatment, which demonstrates the utility of this imaging modality as a non-invasive investigational point-of-care imaging modality for mapping treatment response and identifying the etiology of back pain in a patient with chronic tophaceous spinal gout.

来源:Skeletal Radiol,查看原文。版权归原作者所有。

引用

  1. Saffarzadeh, Haydar, Shojania, et al. Assessing tophaceous spinal gout treatment response using dual-energy CT as a point-of-care imaging modality: case report. Skeletal Radiol. 2022. PMID: 36562821. doi:10.1007/s00256-022-04260-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。